CA2614655A1 - Composition pharmaceutique contenant des inhibiteurs de l'interferon-gamma - Google Patents
Composition pharmaceutique contenant des inhibiteurs de l'interferon-gamma Download PDFInfo
- Publication number
- CA2614655A1 CA2614655A1 CA002614655A CA2614655A CA2614655A1 CA 2614655 A1 CA2614655 A1 CA 2614655A1 CA 002614655 A CA002614655 A CA 002614655A CA 2614655 A CA2614655 A CA 2614655A CA 2614655 A1 CA2614655 A1 CA 2614655A1
- Authority
- CA
- Canada
- Prior art keywords
- ifn
- gamma
- healing
- pharmaceutical composition
- wounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 14
- 102000008070 Interferon-gamma Human genes 0.000 title description 4
- 108010074328 Interferon-gamma Proteins 0.000 title description 4
- 229960003130 interferon gamma Drugs 0.000 title description 2
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 56
- 206010052428 Wound Diseases 0.000 claims abstract description 54
- 230000035876 healing Effects 0.000 claims abstract description 36
- 230000001737 promoting effect Effects 0.000 claims abstract description 24
- 230000037390 scarring Effects 0.000 claims abstract description 21
- 230000002829 reductive effect Effects 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 230000003176 fibrotic effect Effects 0.000 claims abstract description 18
- 230000001684 chronic effect Effects 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 7
- 238000000034 method Methods 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000004936 stimulating effect Effects 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 description 15
- 102000008186 Collagen Human genes 0.000 description 13
- 108010035532 Collagen Proteins 0.000 description 13
- 229920001436 collagen Polymers 0.000 description 13
- 231100000241 scar Toxicity 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000009772 tissue formation Effects 0.000 description 4
- 208000032544 Cicatrix Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 208000025962 Crush injury Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9516967.8 | 1995-08-18 | ||
| GB9516967A GB2304342A (en) | 1995-08-18 | 1995-08-18 | Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma |
| CA2229590A CA2229590C (fr) | 1995-08-18 | 1996-08-09 | Composition pharmaceutique contenant des inhibiteurs de l'interferon- gamma |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2229590A Division CA2229590C (fr) | 1995-08-18 | 1996-08-09 | Composition pharmaceutique contenant des inhibiteurs de l'interferon- gamma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2614655A1 true CA2614655A1 (fr) | 1997-02-27 |
Family
ID=39264242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002614655A Abandoned CA2614655A1 (fr) | 1995-08-18 | 1996-08-09 | Composition pharmaceutique contenant des inhibiteurs de l'interferon-gamma |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2614655A1 (fr) |
-
1996
- 1996-08-09 CA CA002614655A patent/CA2614655A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0783893B1 (fr) | Inhibition de la croissance anormale de cellules synoviales a l' aide d' un antagoniste d'interleukine 6 comme principe actif | |
| BARBUL et al. | The effect of in vivo T helper and T suppressor lymphocyte depletion on wound healing | |
| CA2185565C (fr) | Utilisation de l'il-12 et des antagonistes d'il-12 dans le traitement des maladies auto-immunes | |
| Heremans et al. | Protective effect of anti‐interleukin (IL)‐6 antibody against endotoxin, associated with paradoxically increased IL‐6 levels | |
| US8017121B2 (en) | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component | |
| US7220413B2 (en) | Pharmaceutical composition containing inhibitors of interferon-γ | |
| EP1651266B1 (fr) | Administration de fragments d'anticorps f(ab')2 anti-tnf-alpha | |
| Nicoletti et al. | The effects of a nonimmunogenic form of murine soluble interferon-gamma receptor on the development of autoimmune diabetes in the NOD mouse | |
| US20100305048A1 (en) | Novel use of cytokine inhibitors | |
| EP0968723B1 (fr) | Guérison de plaies ou d'affections fibrotiques utilisant au moins un agent contre un facteur de croissance | |
| JP4616291B2 (ja) | インターフェロン−ガンマスティミュレーター含有医薬組成物 | |
| EP0936923A1 (fr) | SUPPRESSION DU FNT$g(a) ET DE IL-12 EN THERAPIE | |
| US20070020233A1 (en) | Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases | |
| US7727520B2 (en) | Method of promoting the healing of a chronic wound | |
| STEVENS et al. | Synergistic immunosuppressive effects of monoclonal antibodies specific for interferon-gamma and tumor necrosis factor alpha: a skin transplantation study in the rhesus monkey | |
| AU747598B2 (en) | Pharmaceutical composition containing stimulators of interferon-gamma | |
| CA2614655A1 (fr) | Composition pharmaceutique contenant des inhibiteurs de l'interferon-gamma | |
| AU7179491A (en) | Method of treating septic shock | |
| DE69102265T2 (de) | Immunkomplexe. | |
| Oncostatin | Regulation of Inflammatory Responses by | |
| EP0406880A2 (fr) | Méthode stimulant l'activité antitumorale des macrophages et compositions à cet usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |